Sam Brusco, Associate Editor07.26.22
NuVasive released the results of its study "Can a bioactive interbody device reduce the cost burden of achieving lateral lumbar fusion?" in the Journal of Neurosurgery: Spine.
The study validates synthetic solutions featuring porous interbody implants and bone graft substitute having clinical and economic benefits over traditional, non-porous interbodies with premium-priced biologics.
"Having clinically-backed Advanced Materials Science options, from synthetic biologics to porous interbody implants, gives surgeons stronger procedural offerings across the entire spine," Massimo Calafiore, chief commercial officer at NuVasive told the press. "NuVasive leads with a focus on disruptive innovation—providing not only procedures that are better clinically for both patients and surgeons, but also less expensive for the hospitals we partner with."
90 patients underwent lateral lumbar interbody fusions (LLIF) using synthetic bone graft Attrax Putty and the Modulus XLIF porous titanium interbody. The study found use of synthetic biologics and interbodies with advanced surface technologies resulted in a high rate of effective fusion on CT imaging at 12 months, with complete bone bridging in 97.8% of patients, despite use of a small volume of lower-cost biological material.
"I am excited to see outcomes that have been traditionally associated with BMP achieved with cost-effective biologics used in porous interbody cage technology," said Robert Eastlack, MD, orthopedic spine surgeon at Scripps Health in San Diego and board member of the San Diego Spine Foundation. "The results of this study have created lasting change in our practices, presented huge cost savings and showed significant benefits to the patients."
The study validates synthetic solutions featuring porous interbody implants and bone graft substitute having clinical and economic benefits over traditional, non-porous interbodies with premium-priced biologics.
"Having clinically-backed Advanced Materials Science options, from synthetic biologics to porous interbody implants, gives surgeons stronger procedural offerings across the entire spine," Massimo Calafiore, chief commercial officer at NuVasive told the press. "NuVasive leads with a focus on disruptive innovation—providing not only procedures that are better clinically for both patients and surgeons, but also less expensive for the hospitals we partner with."
90 patients underwent lateral lumbar interbody fusions (LLIF) using synthetic bone graft Attrax Putty and the Modulus XLIF porous titanium interbody. The study found use of synthetic biologics and interbodies with advanced surface technologies resulted in a high rate of effective fusion on CT imaging at 12 months, with complete bone bridging in 97.8% of patients, despite use of a small volume of lower-cost biological material.
"I am excited to see outcomes that have been traditionally associated with BMP achieved with cost-effective biologics used in porous interbody cage technology," said Robert Eastlack, MD, orthopedic spine surgeon at Scripps Health in San Diego and board member of the San Diego Spine Foundation. "The results of this study have created lasting change in our practices, presented huge cost savings and showed significant benefits to the patients."